Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review

Abstract Background Antibodies to PD-1 and PD-L1 have remarkably improved the overall survival of many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody. Dermatologic reactive capillary hemangiomas (RCH) were the most common and unique drug-related AEs of SHR-1210, bu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jinhan Zhou, Qinghua Mao, Yining Li, Zhiyong Li, Hong He, Qianming Chen, Chuanxia Liu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Reactive capillary hemangiomas Oral Anti-PD-1 antibody Non-small cell lung cancer Case report Dentistry RK1-715
Acceso en línea:	https://doaj.org/article/d0c0841e52104117a3ef33e702c6daf5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d0c0841e52104117a3ef33e702c6daf5
record_format	dspace
spelling	oai:doaj.org-article:d0c0841e52104117a3ef33e702c6daf52021-11-08T11:04:04ZOral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review10.1186/s12903-021-01901-91472-6831https://doaj.org/article/d0c0841e52104117a3ef33e702c6daf52021-11-01T00:00:00Zhttps://doi.org/10.1186/s12903-021-01901-9https://doaj.org/toc/1472-6831Abstract Background Antibodies to PD-1 and PD-L1 have remarkably improved the overall survival of many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody. Dermatologic reactive capillary hemangiomas (RCH) were the most common and unique drug-related AEs of SHR-1210, but rare on oral mucosa and gastrointestinal mucosa. Herein we report a case of RCH occurred in oral mucosa during the clinical trials of SHR-1210 in the treatment of non-small cell lung cancer. Case presentation A male in his 60 s with a history of non-small cell lung cancer received injection of anti-PD-1 monoclonal antibodies SHR-1210. The patient developed drug-related RCH on skin after the first injection and began to have gingival hyperplasia one year after the first injection which gradually increased in size and affect eating and speaking. Anti-PD-1 treatments were continued. After periodontal treatment, two oral lesions and one skin lesion were surgically removed. Similar histological manifestation was found in all three lesions as reactive capillary hemangiomas. All lesions had a good prognosis without recurrence on oral mucosa within one year after surgery. Conclusions Oral reactive capillary hemangiomas could be induced by SHR-1210 in the treatment of non-small cell lung cancer. Surgical resection is an effective treatment with a good prognosis.Jinhan ZhouQinghua MaoYining LiZhiyong LiHong HeQianming ChenChuanxia LiuBMCarticleReactive capillary hemangiomasOralAnti-PD-1 antibodyNon-small cell lung cancerCase reportDentistryRK1-715ENBMC Oral Health, Vol 21, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Reactive capillary hemangiomas Oral Anti-PD-1 antibody Non-small cell lung cancer Case report Dentistry RK1-715
spellingShingle	Reactive capillary hemangiomas Oral Anti-PD-1 antibody Non-small cell lung cancer Case report Dentistry RK1-715 Jinhan Zhou Qinghua Mao Yining Li Zhiyong Li Hong He Qianming Chen Chuanxia Liu Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
description	Abstract Background Antibodies to PD-1 and PD-L1 have remarkably improved the overall survival of many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody. Dermatologic reactive capillary hemangiomas (RCH) were the most common and unique drug-related AEs of SHR-1210, but rare on oral mucosa and gastrointestinal mucosa. Herein we report a case of RCH occurred in oral mucosa during the clinical trials of SHR-1210 in the treatment of non-small cell lung cancer. Case presentation A male in his 60 s with a history of non-small cell lung cancer received injection of anti-PD-1 monoclonal antibodies SHR-1210. The patient developed drug-related RCH on skin after the first injection and began to have gingival hyperplasia one year after the first injection which gradually increased in size and affect eating and speaking. Anti-PD-1 treatments were continued. After periodontal treatment, two oral lesions and one skin lesion were surgically removed. Similar histological manifestation was found in all three lesions as reactive capillary hemangiomas. All lesions had a good prognosis without recurrence on oral mucosa within one year after surgery. Conclusions Oral reactive capillary hemangiomas could be induced by SHR-1210 in the treatment of non-small cell lung cancer. Surgical resection is an effective treatment with a good prognosis.
format	article
author	Jinhan Zhou Qinghua Mao Yining Li Zhiyong Li Hong He Qianming Chen Chuanxia Liu
author_facet	Jinhan Zhou Qinghua Mao Yining Li Zhiyong Li Hong He Qianming Chen Chuanxia Liu
author_sort	Jinhan Zhou
title	Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
title_short	Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
title_full	Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
title_fullStr	Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
title_full_unstemmed	Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
title_sort	oral reactive capillary hemangiomas induced by shr-1210 in the treatment of non-small cell lung cancer: a case report and literature review
publisher	BMC
publishDate	2021
url	https://doaj.org/article/d0c0841e52104117a3ef33e702c6daf5
work_keys_str_mv	AT jinhanzhou oralreactivecapillaryhemangiomasinducedbyshr1210inthetreatmentofnonsmallcelllungcanceracasereportandliteraturereview AT qinghuamao oralreactivecapillaryhemangiomasinducedbyshr1210inthetreatmentofnonsmallcelllungcanceracasereportandliteraturereview AT yiningli oralreactivecapillaryhemangiomasinducedbyshr1210inthetreatmentofnonsmallcelllungcanceracasereportandliteraturereview AT zhiyongli oralreactivecapillaryhemangiomasinducedbyshr1210inthetreatmentofnonsmallcelllungcanceracasereportandliteraturereview AT honghe oralreactivecapillaryhemangiomasinducedbyshr1210inthetreatmentofnonsmallcelllungcanceracasereportandliteraturereview AT qianmingchen oralreactivecapillaryhemangiomasinducedbyshr1210inthetreatmentofnonsmallcelllungcanceracasereportandliteraturereview AT chuanxialiu oralreactivecapillaryhemangiomasinducedbyshr1210inthetreatmentofnonsmallcelllungcanceracasereportandliteraturereview
_version_	1718442471532265472

Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review

Ejemplares similares